---
schema_version: "secwatch.filing_event.v1"
accession: "0001520138-22-000448"
form_type: "8-K"
ticker: "BIVI"
cik: "0001580149"
company_name: "BIOVIE INC."
filed_at: "2022-10-05T23:59:59+00:00"
generated_at: "2026-06-23T05:21:56.931150+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioVie reports 82% responder rate in Phase 2 Alzheimer's study; Phase 3 on track for mid-2023 readout

## Summary
- 82% of MCI/mild AD patients improved cognition (modified ADAS-Cog12) after 3 months; mean improvement -2.6 points (p=0.0046).
- Phase 3 NE3107 Alzheimer's trial has enrolled >50% of 316 patients; topline data expected mid-2023.
- Phase 2 Parkinson's NE3107 trial expected to read out by end of 2022; early blinded data consistent with animal studies.
- Phase 2b BIV201 ascites trial enrollment slowed by COVID; topline data now expected mid-2023.
- Full data from exploratory Alzheimer's study to be presented at CTAD conference Nov 29–Dec 2, 2022.

## SEC filing metadata
- accession: 0001520138-22-000448
- form_type: 8-K
- ticker: BIVI
- cik: 0001580149
- company_name: BIOVIE INC.
- filed_at: 2022-10-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580149/000152013822000448/0001520138-22-000448-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580149/000152013822000448/bivi-20221004_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001520138-22-000448
- JSON: https://secwatch.observer/filing/0001520138-22-000448.json
- Plain text: https://secwatch.observer/filing/0001520138-22-000448.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.